Novartis

ADAKVEO

Manufacturer:

Novartis

Adakveo HCPCS:

J0791

HCPCS Code Descriptor:

Injection, crizanlizumab-tmca, 5 mg

Category:

J Code

Adakveo NDCs:

00078-0883-61

Primary Type:

Oncology-Anti-Emetic

Generic/Specialty Status:

Single-Source

Package Type:

Vial

Route of Administration:

Intravenous

Adakveo CPT Codes:

Potential CPT administration codes for Adakveo can be found at the following link.

Potential NDC Listing Errors:

Our team did not identify any potential listing errors/discrepancies for the NDCs mapped to this HCPCS code.

About Adakveo:

ADAKVEO is an Oncology-Anti-Emetic drug manufactured by Novartis and administered via the Intravenous route of administration. The J Code: J0791 is aligned to the drug ADAKVEO.

ACCESS PRICING AND MORE BY REGISTERING

J0791 Added Date:

July 1, 2020

J0791 Effective Date:

July 1, 2020

J0791 Termination Date:

HCPCS Active

Adakveo billing and coding information can be found through Novartis at the link below:
Adakveo patient assistance information can be found through Novartis Patient Support at the URL: https://www.patient.novartisoncology.com/financial-assistance/pano/
ADAKVEO prescribing information can be found at the link below:
Information regarding ADAKVEO’s side effects can be found at MedlinePlus